Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Elpiscience Starts Australian Trial of Anti-Immunosuppressive Candidate

publication date: Sep 26, 2023

Elpiscience, a Shanghai-Suzhou oncology immunotherapy company, has dosed the first patient in an Australian Phase trial of ES009, an anti-LILRB2 monoclonal antibody. LILRB2 is an inhibitory receptor expressed on the surface of myeloid cells that contributes to immune suppression in the tumor microenvironment. ES009 binds to an epitope on human LILRB2, blocking LILRB2 binding to multiple ligands. This reprograms myeloid cells from an anti-inflammatory phenotype into a pro-inflammatory phenotype, allowing T cells to function. The trial is enrolling patients with advanced solid tumor cancers. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital